Concomitant administration ritonavir and glucocorticoids metabolised by via the P450 3A pathway is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects. A switch to a glucocorticoid, which is not a substrate for CYP3A4 (e.g. beclomethasone) should be considered.

Norvir Summary of Product Characteristics, AbbVie, September 2016.

The effect of ritonavir (100 mg twice daily) or darunavir/ritonavir (600/100 mg twice daily) on the pharmacokinetics of inhaled beclomethasone diproprionate (160 mg twice daily) and adrenal function were investigated in groups of 10 HIV- subjects.  Coadministration of ritonavir alone increased the AUC and Cmax of beclomethasone-17-monoproprionate (the active metabolite) by 108% and 67%, respectively.  Conversely, coadministration of darunavir/ritonavir decreased the AUC and Cmax of the active metabolite by 11% and 19%, respectively. No significant effect on adrenal function was seen with either ritonavir or darunavir/ritonavir. Although statistically significant, the authors state that the 2-fold increase in AUC of the active metabolite seen with ritonavir would be clinically inconsequential and in HIV-infected patients receiving a PI and requiring an inhaled corticosteroid, inhaled beclomethasone is preferable to fluticasone. Moreover, these data show that PK results from drug interaction studies using ritonavir alone do not always predict the magnitude of interaction when ritonavir is co-administered with another PI.
Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone. Boyd SD, Hadigan C, McManus M, et al. J Acquir Immune Defic Syndr. 2013, 63(3):355-61.